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Q1. how would you assess? 
Q2. what investigations you would like to have? 












Q1. What information you would gather? 




































































Holma KM, J Clin Psychiatry. 2008 Feb;69(2):196-205. 
• 269 patients with a new episode of MDD were enrolled,  Axis I 
and II comorbidity was assessed 
•  majority (79%) of patients with MDD suffered from 1 or more     
current comorbid mental disorders, 
•  anxiety disorder (57%),  
•  alcohol use disorder (25%),   
•  personality disorder (44%). 
•  Comorbid disorders are associated  with sociodemographic 
factors,  
•  inpatient versus outpatient status, 
•  lifetime number of depressive episodes.   
Current comorbidity of psychiatric disorders 
among DSM‐IV major depressive disorder 





















































1.Bipolar spectrum, 2. Serotonin Spectrum,  

















•  Parkinson’s     : 40% 
•  Hun=ngton's    : 40% 
•  CVA                 : 30‐50% 
•  MS                   : 10‐50% 
•  Alzheimer’s    : 15‐55% 

















Ran out of 
pills 
Common reason for discontinuation 





























































































































































































































































































































































































































































Vieta E, et al. Bipolar Disord 2005; 7 Suppl 4:21-33.  
Lifelong management of this lifelong illness involves  
targeting all phases of the disorder – atypical antipsychotics  











Bipolar II disorder: a review. 
Berk M, Dodd S. 

























































































































































































































                   MOOD DISORDER 
                         | 
                         | 
      --------------------------------------------------------- 
      |                                                         | 
      |                                             DEPRESSIVE DISORDERS 
BIPOLAR DISORDERS                                              | 
           |                                                    | 
           |                                      episodic--------------chronic 
 episodic-------chronic                              |                     | 
    |             |                                   |                     |  
    |             |                             MAJOR DEPRESSION       DYSTHYMIA 
BIPOLAR       CYCLOTHYMIA                           | 
    |                                                  -------------------------------  
 --------------------                       psychotic/     melancholia/     |  
 |                  |                      nonpsychotic   no melancholia    | 
psychotic/          |                           |                           |  
nonpsychotic        |                           |                     seasonal/ 
   |            seasonal/                       |                  not seasonal 
   |           not seasonal                mood congruent/ 
   |                                        incongruent  















A lifelong, chronic and devastating 
affective disorder, characterised by 
recurrent episodes of major disturbance 
at the two ‘poles’ of mood disturbance: 






























CANMAT Guidelines for Bipolar Disorder. Bipolar Disord 2005: 7 (Suppl. 3): 5–69. 
American Psychiatric Association 2000; Judd et al 2002; Tondo et al 2003; 























*p<0.05; ***p<0.001 vs treated patients n=220 
Untreated 
*** 




Angst et al 2002 
Time Spent in Speciﬁc Bipolar Disorder Aﬀec=ve
 Symptoms 
*%s do not add to 100 due to rounding 
Judd LL et al. Arch Gen Psychiatry. 2002;59:530-537. 




























Judd LL et al. Arch Gen Psychiatry. 2002;59:530-537. 
Judd LL et al. Arch Gen Psychiatry. 2003;60:261-269. 
Psychosocial Outcome in Bipolar Disorder 
•  Avg 14.1 years of 
illness 
-  5.2 depressions 
-  3.6 manias 




•  Number of manias not 
a strong predictor of 
function GAF=Global Assessment of Functioning MOS=Medical Outcomes questionnaire Short form 


















* * P < .0001 
  N = 2,450 
Subjects with impact ratings of 8, 9, or 10  
as assessed by the Sheehan Disability Scale 
MDQ positive 
MDQ negative 
Calabrese JR et al. J Clin Psychiatry. 2003;64:425-432. 
MDQ = Mood Disorder Questionnaire 
Impact of Bipolar Disorder on Pa=ents’
 Lives 
Healthy life Reduced by 12 years 
Working life Reduced by 14 years 
Life expectancy Reduced by 9 years 
Employment problems Twice as common 
Divorce / separation Twice as common 
Onset is usually during late adolescence and early adulthood, a time at which
 individuals are establishing their careers and building long-term relationships 
Results for patients developing bipolar disorder in their mid-20s 
















 Hirschfeld RM et al. J Clin Psychiatry. 2003a:64:53-59. 





















•  The prevalence and 
epidemiology of 
psychiatric 
comorbidities in bipolar 
disorder is high 












Greater risk of 
depressive and mixed 




















































Little to mild dysfunction Severe dysfunction 
Little to mild, lapses of judgment Major lapses of judgment 
Commonly responds to outpatient 
management 
Often requires inpatient treatment 
Non-psychotic symptoms Psychotic symptoms 


























Symptom Remission  
Maintain Functioning 





























N=200 2-y follow-up 










































Olanzapine (Zyprexa®) √ √* 
Quetiapine (SEROQUEL XR®) √ √ 
Risperidone (Risperdal®) √ 
Paliperidone (Invega ®) 
Ziprasidone (Zeldox®) 
OTHER 
Carbamazepine  √ √+ 
Divalproex  √ 
Lamotrigine  
Lithium  √ √ 
+ for use after treatment failure on traditional mood stabilizer 
*See PM.  Evaluation from 2 “time to relapse” trials with manic or 
mixed index episode 
Health Canada Approved Indica=ons for Agents Used in
 the Treatment of Bipolar Disorder 
This chart does not imply comparable efficacy or 
safety profiles.   
All brand names and product names used in this slide 
are trade names, service marks, trademarks, or 
registered trademarks of their respective owners. 
